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TaiwanResults: A total of 46 cases were identified including 25 males and 21 females with a median
age of 63.5; 18 (39%) were at stage I and 28 (61%) at stage II. Seven (15%) patients underwent
surgery as initial treatment including total (n Z 3, 7%) and subtotal (n Z 4, 9%) gastrectomy.
Thirty-three patients (72%) received frontline chemotherapy treatment including ten with
additional rituximab (MabThera) injection, and two (6%) of these patients developed perfora-
tion after chemotherapy. Four patients passed away shortly after diagnosis and the remaining
three were lost to follow-up. The overall 2- and 5- year survival rates were 55% and 50%,
respectively. The expression of various differentiation markers was CD10 (25%), bcl-2 (50%),
bcl-6 (84%), and MUM1 (64%). Half of the cases studied (22/44) were classified as germinal
center B-cell (GCB) phenotype and the remaining half as non-GCB according to Hans algorithm;
66% and 34% cases belonged to groups 1 and 2, respectively, according to Muris algorithm.
Univariate analysis showed the expression of bcl-6 by the tumor cells as a favorable factor,
while elevated serum lactate dehydrogenase (LDH) level, bcl-2 expression, and Muris group
2 were associated with poorer outcome. Multivariate analysis revealed that the two prognostic
factors were bcl-6 expression and elevated LDH level, with hazard ratios of 0.09 (p Z 0.002)
and 3.72 (p Z 0.024), respectively.
Conclusion: In this retrospective study with heterogeneous treatment modality, we identified
bcl-6 expression and elevated LDH level as two prognostic factors for PG-DLBCL.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
The gastrointestinal tract is the most common organ for
primary extra-nodal non-Hodgkin lymphoma (NHL).1 Most
primary gastrointestinal lymphomas occur in the stomach
with mucosa-associated lymphoid tissue (MALT) lymphoma
and diffuse large B-cell lymphoma (DLBCL) as the most
frequent histological types.2e5 DLBCL is the most common
type of lymphoma worldwide and is clinically and biologi-
cally heterogeneous.6 Clinically, patients differ in their
mode of presentation and respond variably to therapy. A
combination of clinical parameters such as Eastern Coop-
erative Oncology Group performance status (PS), Ann Arbor
stage, lactate dehydrogenase (LDH) level, and International
Prognostic Index (IPI) can be used to predict response to
therapy and survival.7 Pathologically, DLBCL differ in
morphology, immunophenotype, and genetic features.
Numerous markers detectable by immunohistochemistry
and linked to different aspects of tumor biology have been
studied in DLBCL including more recently, stage-specific
markers of B-cell differentiation.8
There have been several studies on primary gastric (PG)
MALT lymphomas including those with high-grade trans-
formation from Taiwan, yet there are scanty reports on PG-
DLBCL.9e11 In a previous study of 30 cases with primary
intestinal DLBCL from Taiwan, we identified perforation as
the only poor prognostic factor.12 In this retrospective
study, we aimed at elucidating the clinicopathological
features of PG-DLBL in Taiwan in the hope of identifying the
prognostic factors.
Material and methods
We retrospectively searched the lymphoma database for
gastric DLBCL from January 1994 to December 2008 at the
Chi-Mei Medical Center, Tainan, Taiwan. Strict inclusion
criteria for PG lymphoma were applied according to the
American Joint Committee on Cancer Staging Manual,which is a modification of the Ann Arbor System.13 We
excluded cases of PG MALT lymphomas with high-grade
transformation and systemic lymphomas with secondary
gastric involvement. This study was approved by our Insti-
tutional Review Board.
Specimens were preserved in 10% formalin, processed by
routine methods, and embedded in paraffin. All of the
original hematoxylin and eosinestained sections (HE-
stained sections) and/or newly cut and HE-stained sections
were reviewed. Immunohistochemical staining on 4-mm
sections was performed for each case with either the
labeled streptavidinebiotin peroxidase method (LSAB kit,
Dako Corp., Carpinteria, CA, USA) or a polymer-based
detection system (Bond Polymer Refine Detection, Vision
BioSystems Ltd., Newcastle Upon Tyne, UK), and an
antigen-retrieval technique was applied as needed for each
antibody. The antibodies used were CD3, CD20, CD21, bcl-
2, bcl-6, IRF4/MUM1 (MUM1p), Ki-67 (MIB-1) (DakoCytoma-
tion, Glostrup, Denmark), and CD10 (Novocastra, Newcastle
upon Tyne, UK). Appropriate positive controls were used for
all immunohistochemical staining. For the interpretation of
CD10, bcl-2, bcl-6, and IRF4/MUM1, positive signals 30% of
neoplastic cells were considered to be positive. We applied
the algorithms of Hans et al and Muris et al to categorize
the cases into germinal center B-cell (GCB) versus non-GCB
phenotype and groups 1 versus 2, respectively, for prog-
nostic stratification.14,15
Staging procedure included computed tomography,
magnetic resonance imaging and/or positron emission
tomography scans of the chest and abdomen, and bone
marrow aspiration and biopsy. Patients were staged
according to the criteria proposed by the International
Workshop for gastrointestinal NHL.16 Medical records of the
patients were reviewed. Progression-free survival rate was
defined as the time from diagnosis to progression, relapse
or death from any cause. The overall survival (OS) rate was
measured from the date of diagnosis to the date of last
follow-up or death. Cox proportional hazard regression
analyses were performed to estimate the hazard ratio (HR)
384 K.-M. Chung et al.of predictors. KaplaneMeier survival curves were drawn
and log-rank test was used to compare differences between
survival curves. All statistical analyses were performed
using SPSS version 12.0.7 for Windows (SPSS Inc., Chicago,
IL, USA). A p value < 0.05 was considered to be statistically
significant.Results
We identified 53 patients with gastric DLBCL from initial
search. One patient with stage III and four patients with
stage IV disease were excluded, as we could not definitely
differentiate between primary and secondary gastric
lymphomas. Two patients with coexisting MALT lymphoma
were also excluded from our study. Therefore, only the
remaining 46 cases were included in this study. Table 1
summarizes the pertinent clinicopathological findings of
these patients, including 25 males and 21 females
(M:F Z 1.2:1). The median age was 63.5 years with
a range of 14e87 years. Eighteen (39%) patients were at
stage I and 28 (61%) were at stage II. Seven (15%) patients
underwent surgery as initial treatment including total
(n Z 3, 7%) and subtotal (n Z 4, 9%) gastrectomy. Thirty-
three patients (72%) received combination chemotherapy
with COP [cyclophosphamide, vincristine, (Oncovin) and
prednisolone; 10 patients (22%)] or CHOP [cyclophospha-
mide, doxorubicin, vincristine (Oncovin) and predniso-
lone; 23 patients (50%)] as frontline therapy. One patient
in the COP-treated group and nine patients in CHOP-
treated groups were also treated with rituximab. Of
these 33 patients, 3 subsequently underwent subtotal
gastrectomy due to gastric outlet obstruction (Case 32) or
perforation (Cases 19 and 26; 6%). Of these two patients,
one died of this complication 10 days later (Case 19),
while the other was free of disease for 88 months when
examined at the last follow-up (Case 26). Two patients
received radiotherapy, including Patient No. 30 as salvage
therapy for relapsed tumor (4600 cGy to neck nodes and
5040 cGy to para-aortic nodes and spleen) and No. 36 as
adjuvant therapy (4200 cGy) following R-CHOP. Four
patients passed away shortly after biopsy (0.3e2.0
months) without chemotherapy either due to old age,
poor PS, or severe co-morbidity; three patients were lost
to follow-up.
We stratified the nonsurgically treated patients into
three groups: supportive care without chemotherapy,
chemotherapy with either COP or CHOP-like regimens. The
OS curves of these three groups of patients are depicted in
Fig. 1. The only statistically significant comparison was
between COP and CHOP (p Z 0.025; log-rank test), while
there was no statistical significance between no chemo-
therapy and COP (pZ 0.784) or no chemotherapy and CHOP
(p Z 0.073) groups. The median OS time of patients
receiving CHOP-based chemotherapy was 61 months. The
progression-free and OS curves are depicted in Fig. 2. The
median progression-free and OS time were 17 and 46
months, respectively. The 2- and 5- year OS rates of the
entire cohort were 55.3% (95% CI: 40.8e69.8%) and 50.0%
(95% CI: 35.1e64.9%), respectively.
Histopathologically, all tumors showed diffuse infiltra-
tion of medium to large atypical lymphocytes withoutlymphoepithelial lesion or any low-grade component
(Fig. 3). Immunophenotypically, all tumors expressed CD20
but not CD3. Staining with anti-CD21 identified no follic-
ular dendritic meshworks. No tumor tissue was left for
immunohistochemical study of differentiation antigens in
the two cases (Cases 6 and 12). Of the remaining 44 cases,
the expression of various differentiation markers in
a decreasing order was bcl-6 (84%), MUM1 (64%), bcl-2
(50%), and CD10 (25%). According to the algorithm of
Hans et al, half of the cases (22/44) were classified as GCB
and the remaining half as non-GCB.14 According to the
criteria of Muris et al, 66% and 34% cases were groups 1 and
2, respectively.15
Table 2 lists the prognostic significance of various clin-
ical and laboratory parameters, differentiation markers,
and phenotypic grouping using univariate Cox proportional
hazard regression model. Bcl-6 expression was associated
with a favorable outcome (HR: 0.23; p Z 0.004), while
elevated LDH level (HR: 3.20; p Z 0.031), bcl-2 expression
(HR: 2.57; p Z 0.043), and Muris group 2 (HR: 2.43;
p Z 0.048) were associated with poorer prognosis. The
other B-cell differentiation antigens (CD10 and MUM1), Ki-
67 labeling index (S80% vs. <80%), and GCB versus non-
GCB by Hans algorithm were not related to prognosis. All
the other clinical parameters including gender, age at
diagnosis (S60 vs. <60), diagnostic method (biopsy vs.
subtotal or total gastrectomy), PS (0e1 vs. 2e4), IPI score
(0e1 vs. 2e5), and stage (I vs. II) were of no prognostic
significance. All variables in the univariate analysis with
p < 0.2 were included for multivariate analysis using Cox
proportional hazard regression model, while bcl-6 expres-
sion (HR: 0.09; 95% CI: 0.02e0.42; pZ 0.002) and elevated
LDH level (HR: 3.72; 95% CI: 1.19e11.68; p Z 0.024)
remained prognostically significant.Discussion
Previous series have identified various clinical prognostic
parameters such as early-stage detection, younger age, and
radical surgery in patients with PG lymphoma.17e19 In these
studies, however, patients with diseases with low-grade
component (MALT lymphoma) and/or with high-stage
disease had been included. The survival probability for
patients with gastric MALT lymphomas is significantly better
than patients with secondary high-grade transformation or
de novo PG-DLBCL; whereas the survival of the latter two
high-grade tumor groups is usually not significantly
different.20 In our study focusing only on patients with pure
PG-DLBCL at low-stage diseases, we found that the two
prognostic variables were bcl-6 expression by the tumor
cells and elevated LDH level but not other clinical param-
eters. In a study of Hong KongeChinese population with PG-
DLBCL and gastric MALT lymphoma with high-grade
component, high bcl-6 expression predicted better prog-
nosis, independent of BCL6 translocation status, trans-
location partner, or BCL6-deregulation mutations.21 In
a Japanese study of 29 cases of pure PG-DLBCL without
a low-grade component, the expression rate of CD10 (41%),
bcl-2 (28%), and bcl-6 (76%) was comparable to ours (25%,
50%, and 84%, respectively); and bcl-6 expression was one
of two favorable prognostic factors in addition to stage
Table 1 Clinical and laboratory parameters, immunohistochemistry, and phenotype in primary gastric DLBCL.
No./gender/
age
Stage Dx method C/T ECOG-PS IPI Immunohistochemistry Hans Muris PFS (m) Outcome (m)
CD10 bcl-2 bcl-6 MUM1 Ki-67
1/F/49 II Biopsy COP 1 NA  þ þ þ 70 Non-GCB 2 9 DOD (10)
2/M/63 II Subtotal Nil 1 NA   þ  60 GCB 1 120 NED (120)
3/M/65 I Biopsy CHOP 1 NA þ  þ þ 80 GCB 1 0 DOD (3)
4/M/71 I Biopsy Nil 3 NA  þ þ  50 GCB 1 0 LTF (8.5)
5/F/60 I Subtotal Nil 1 1  þ þ þ 90 Non-GCB 2 43 DOD (43)
6/F/66 II Biopsy COP 1 NA ND ND ND ND ND NA NA 44 DOD (46)
7/F/59 I Total Nil 1 NA   þ  40 GCB 1 27 DOD (28)
8/F/76 I Biopsy Nil 3 NA   þ þ 70 GCB 1 0 LTF (10)
9/F/80 II Subtotal Nil 1 NA þ þ þ þ 90 GCB 1 7 DOD (7)
10/F/51 II Biopsy CEOP 1 1 þ  þ  95 GCB 1 0 DOD (6)
11/F/58 II Biopsy COP 1 1  þ   80 Non-GCB 1 0 DOD (2)
12/F/65 II Biopsy CEOP 1 1 ND ND ND ND ND NA NA 8 DOD (9)
13/F/82 II Biopsy COP 2 NA  þ  þ 40 Non-GCB 2 0 DOD (2)
14/M/81 I Biopsy Nil 4 NA  þ   90 GCB 1 0 DOD (1.5)
15/M/35 II Biopsy CEOP 0 2 þ   þ 90 Non-GCB 1 0 DOD (4)
16/M/52 II Biopsy CEOP 0 1   þ  40 GCB 1 20 DOD (22)
17/F/52 I Biopsy CEOP 1 1   þ þ 40 Non-GCB 1 122 NED (122)
18/M/48 II Biopsy CEOP 1 0   þ  ND GCB 1 111 NED (111)
19/F/65a II Biopsy COP 1 1  þ þ þ ND Non-GCB 2 0 DOD (6)
20/M/14 II Biopsy CEOP 1 0 þ  þ  70 GCB 1 106 NED (106)
21/F/73 II Biopsy Nil 4 NA  þ þ þ ND Non-GCB 2 0 DOD (0.3)
22/F/50 II Subtotal R-CHOP 1 0  þ þ  ND GCB 1 92 NED (92)
23/F/61 I Biopsy Nil 0 NA   þ þ ND Non-GCB 1 0 LTF (1)
24/F/75 II Biopsy COP 1 1  þ  þ ND Non-GCB 2 0 DOD (5)
25/M/41 II Biopsy CEOP 1 0 þ  þ  100 GCB 1 91 NED (91)
26/M/66a I Biopsy CEOP 1 1   þ  100 GCB 1 88 NED (88)
27/M/62 I Biopsy CEOP 1 2  þ þ þ 80 Non-GCB 2 70 DOD (75)
28/M/76 II Biopsy COP 1 1 ND  þ þ 95 Non-GCB 1 80 NED (80)
29/M/62 II Biopsy R-CHOP 1 2 þ þ þ þ 60 Non-GCB 2 85 NED (85)
30/F/55b II Biopsy CEOP 1 0   þ þ 80 Non-GCB 1 35 AWD (91)
31/M/34 I Biopsy R-CHOP 1 0 þ þ þ þ 95 GCB 1 73 NED (73)
32/M/69a II Biopsy R-CHOP 2 2   þ  100 GCB 1 42 DOUD (42)
33/M/57 I Biopsy CHOP 1 0   þ  90 GCB 1 64 NED (64)
34/M/58 I Biopsy CHOP 1 0  þ þ þ 90 Non-GCB 2 61 NED (61)
35/M/65 II Biopsy COP 3 3   þ  90 GCB 1 0 DOD (1)
36/M/48b I Biopsy R-CHOP 1 0   þ þ 90 Non-GCB 1 60 NED (60)
37/M/68 I Biopsy Nil 4 3  þ  þ 90 Non-GCB 2 0 DOD (2)
38/F/82 I Total Nil 1 NA  þ  þ 90 Non-GCB 2 54 NED (54)
39/F/76 II Biopsy Nil 4 3  þ þ þ 90 Non-GCB 2 0 DOD (2)
40/M/51 II Biopsy R-CHOP 2 4 þ  þ þ 90 GCB 1 0 DOD (4.2)
41/F/77 I Biopsy R-COP 1 2   þ  90 GCB 1 68 NED (68)
42/M/73 II Total Nil 2 3 þ þ þ þ 90 GCB 1 0 DOD (1.5)
43/F/76 II Biopsy COP 2 3  þ þ þ 90 Non-GCB 2 0 DOD (3.5)
44/M/79 I Biopsy R-CHOP 2 3  þ þ þ 90 Non-GCB 2 7 DOD (7)
45/M/87 II Biopsy R-CHOP 1 2 þ  þ þ 90 GCB 1 30 DOUD (30)
46/M/61 I Biopsy R-CHOP 1 1  þ þ þ 70 Non-GCB 2 38 NED (38)
AWD Z alive with disease; C/T Z chemotherapy; COP Z cyclophosphamide, vincristine (Oncovin), and prednisolone;
CEOP Z cyclophosphamide, epirubicin, vincristine (Oncovin), and prednisolone; CHOP Z cyclophosphamide, doxorubicin, vincristine
(Oncovin), and prednisolone; Dx Z diagnosis; DOD Z died of disease; DOUD Z died of unrelated disease; ECOG-PS Z Eastern Coop-
erative Oncology Group performance status; GCB Z germinal center B-cell phenotype; IPI Z International Prognostic Index; Ki-67,
labeling index (%) as determined by Ki-67 immunohistochemistry; LTF Z lost to follow-up; NA Z not available; ND Z not done;
NED Z no evidence of disease; PFS Z progression-free survival; R-COP Z rituximab plus COP; R-CHOP Z rituximab plus CHOP;
subtotal Z subtotal gastrectomy; Total Z total gastrectomy.
a These three patients received chemotherapy as initial treatment, developed gastric outlet obstruction (Case 32) or perforation
(Cases 19 and 26) and subsequently underwent subtotal gastrectomy.
b These two patients received radiotherapy: No. 30 as savage therapy for relapsed tumors; No. 36 as adjuvant therapy following
R-CHOP.
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Figure 1 Overall survival curves of patients with primary
gastric diffuse large B-cell lymphoma stratified by no chemo-
therapy, and chemotherapy with COP and CHOP, respectively.
Figure 2 (A) Progression-free survival and (B) overall survival
of patients with primary gastric diffuse large B-cell lymphoma.
386 K.-M. Chung et al.classification of the disease.22 Bcl-6, a marker of GCB
origin, is encoded by BCL6 proto-oncogene located at the
3q24 locus with pivotal roles in germinal center formation
and regulation of lymphocyte function, differentiation, and
survival. BCL6 is a frequently activated oncogene in the
pathogenesis of human B-cell lymphoma, most of which are
derived from GCB.23,24 The expression of bcl-6 protein has
been associated with a favorable prognosis in DLBCL.8,25
The prognostication of DLBCL in the rituximab era might
be different from the earlier prognostic models.26 Winter
et al showed that in bcl-6-negative DLBCL patients, failure-
free survival (FFS) and OS rates were prolonged in those
treated only with R-CHOP compared to CHOP treatment
alone. In contrast, no differences in FFS and OS rates were
detected between treatment arms for bcl-6-positive
cases.27 In our study, the number of patients treated with
R-CHOP was too small for a meaningful statistical analysis.
Prospective studies on treatment using R-CHOP are war-
ranted to examine whether bcl-6 expression retains its
prognostic value in PG-DLBCL.
DLBCL is a heterogeneous disease.6 Using a complemen-
tary DNA microarray method, DLBCLs could be divided into
prognostically important subgroups: GCB-like and non-GCB-
like.28,29 Patients with GCB-like DLBCL had a significantly
better OS rate than those with non-GCB type. Hans et al
reported the first immunohistochemical algorithm as
a surrogate method for genetic profiling to predict prog-
nostic impact in DLBCL and the effectiveness of their
algorithm has been proved in various studies.14,30,31
Subsequently, Muris et al used immunohistochemical
profiling based on bcl-2, CD10, and IRF4/MUM1 expression,
yet its prognostic utility is conflicting, particularly when
rituximab is included in the chemotherapeutic
regimen.15,27,32 Very recently, Meyer et al comparedvarious algorithms on a large cohort of DLBCL patients
treated with R-CHOP or R-CHOP-like therapy.33 They found
that Hans and Choi algorithms had high concordance with
the microarray results and Tally algorithm showed the best
concordance with the microarray data while maintaining
the prognostic significance and ease of use with only four
antibodies (CD10, MUM1, GECT1, and FoxP1) without regard
to the order of examination.33 In a recent study on de novo
DLBCL by Gutie´rrez-Garcı´a et al comparing gene expression
profiling (GEP) and immunohistochemical algorithms, the
GEP groups showed significantly different better 5-year
progression-free survival and OS rates in the GCB group
than the activated B-cell group; in contrast, none of the
Figure 3 A representative case of primary gastric lymphoma. (A) and (C) Gross and microscopic scanning power showing
a polypoid tumorous lesion with transmural infiltration of lymphoma cells. (B) High-power view shows diffuse infiltration of large
lymphoma cells with centroblastic morphology and gastric epithelial cells at the left-lower corner. The tumor cells express bcl-6 (F)
but not CD10 (D), bcl-2 (E) or MUM1 (G), a GCB phenotype by Hans algorithm and type 1 by Muris algorithm.
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Choi, and Tally) was able to retain the prognostic impact of
the groups (GCB vs. non-GCB).34 While in patients with
relapsed/refractory DLBCL, Thieblemont et al showed that
the GCB phenotype based on the Hans algorithm was
significantly associated with a better progression-free
survival in the rituximab, dexamethasone, high-dose
cytarabine, and cisplatin (R-DHAP) arm.35 Whetherimmunohistochemical algorithms could be used as surro-
gate markers for GEP is controversial and is a subject of
debate; however, as pointed out by Gutie´rrez-Garcı´a et al,
stratification of DLBCL cases based on immunostaining
algorithms should be used with caution in guiding therapy,
even in clinical trials.34
The algorithm of Hans et al is the most widely applied,
probably in part because the markers used (CD10, bcl-6,
Table 2 Univariate Cox proportional hazard regression
model for prognostic markers in primary gastric diffuse
large B-cell lymphoma.
Variables HR 95% CI p
Lower Upper
Gender (M vs. F) 0.54 0.24 1.25 0.150
Age (>60 vs. &60) 2.02 0.83 4.93 0.122
Dx method (surgery vs. Bx) 0.67 0.20 2.27 0.525
LDH (elevated vs. normal) 3.20 1.11 9.17 0.031
Stage (II vs. I) 1.35 0.87 2.07 0.178
ECOG-PS (2e4 vs. 0e1) 1.25 0.78 2.00 0.359
IPI (0e1 vs. 2e5) 0.46 0.16 1.34 0.156
C/T (yes vs. no) 0.60 0.25 1.45 0.270
CD10 (positive vs. negative) 1.14 0.44 2.95 0.784
bcl-2 (positive vs. negative) 2.57 1.03 6.41 0.043
bcl-6 (positive vs. negative) 0.23 0.09 0.62 0.004
MUM1 (positive vs. negative) 1.69 0.65 4.37 0.282
Ki-67 index (S80 vs. <80) 0.81 0.53 1.25 0.340
Hans et al (GCB vs. non-GCB) 1.78 0.58 5.42 0.312
Muris et al (group 2 vs. 1) 2.43 1.01 5.87 0.048
Bx Z biopsy; C/T Z chemotherapy; CI Z confidence interval;
Dx Z diagnosis; ECOG-PS Z Eastern Cooperative Oncology
Group performance status; GCB Z germinal center B-cell;
HR Z hazard ratio; IPI Z International Prognostic Index;
LDH Z lactate dehydrogenase.
388 K.-M. Chung et al.and MUM1/IRF4) are readily available in the majority of
pathology laboratories, which are useful in the differential
diagnosis of Burkitt lymphoma in conjunction with bcl-2 and
Ki-67.14,36 In this study, there was an equal distribution of
GCB (50%) and non-GCB phenotypes in PG-DLBCL. In our
previous study of 30 patients with surgically resected
primary intestinal DLBCLs, the proportion of GCB pheno-
type was 30%, showing no prognostic impact of differenti-
ation antigens or GCB and non-GCB phenotypes based on
the Hans algorithm.12 In a recent British study of PG and
intestinal DLBCLs using the same algorithm, 27% (4/15
cases) of gastric tumors were of GCB type as compared with
64% (9/14) of intestinal tumors.37 In that study, the
differentiation antigens or GCB versus non-GCB phenotype
did not carry any prognostic significance in either the PG or
intestinal DLBCL groups. Another study from the US also
revealed differences in GCB versus non-GCB phenotype in
PG [58% (14/24 cases) GCB] and intestinal [88% (19/22)
GCB] DLBCL groups; again, there was no significant differ-
ence in either OS or disease-free survival between the GCB
and non-GCB groups.38 These reports indicate a difference
in the distribution of GCB versus non-GCB phenotype in
gastric and intestinal DLBCL among various geographic
regions, possibly reflecting the impact of ethnic and envi-
ronmental factors in lymphomagenesis. Furthermore, the
differentiation antigens or Hans algorithm did not have
a prognostic impact, suggesting that other factors may play
important roles for prognosis.
Perforation is a frequent presentation of primary intes-
tinal lymphomas in Taiwan, particularly in those with T-cell
phenotype.12,39 As T-cell lymphomas are generally more
aggressive than their B-cell counterparts, the higher rateof perforation might be an indicator of biological aggres-
siveness.12,39 While none of the patients presented with
perforation in our current study, the occurrence of acute
gastric perforation or gastrointestinal hemorrhage in
patients with PG lymphoma is a recognized rare complica-
tion of chemotherapy, with a rate of <5% in most
studies.40,41 In our study, 2 of 33 patients (6%) developed
gastric perforation after frontline chemotherapy and 1
passed away 10 days after undergoing subtotal gastrec-
tomy. Although perforation is a rare complication, Maisey
et al suggested that routine admission for the initiation of
chemotherapy for PG lymphoma was not necessary and all
patients should receive comprehensive education about the
risks and clinical signs of gastric perforation and bleeding.41
In summary, we characterized the clinicopathological
features of PG-DLBCL in Taiwan, where the outcome was
poor, partly due to old age, high PS scores, and co-
morbidity of some patients. Although this was a retrospec-
tive study with a limited case number and heterogeneous
treatment modalities, we identified bcl-6 expression as
a favorable prognostic marker and elevated LDH level as
a poor prognosticator. In the other retrospective study
involving a total of 423 consecutive DLBCL patients from
May 1989 to December 2010 at our institution, we found
bcl-6 protein expression to be a favorable prognostic factor
(p Z 0.017; multivariate Cox proportional hazard regres-
sion model) in addition to age (Chang et al, manuscript in
preparation). Prospective studies are warranted to examine
whether bcl-6 expression and LDH level retain their prog-
nostic significance in PG-DLBCL in the rituximab era.Acknowledgments
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